Ablysinol is one of 125 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
307 competitors in Pancreatic Cancer
Ablysinol
Medrol
Byetta
MS Contin
Xylocaine
Feraheme
Active Comparator
Secretin-Ferring
Sulfonylureas
Cyclophosphamid
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
Jun 21, 2018
ABLYSINOL
NDA NDA207987
Oct 23, 2025
DEHYDRATED ALCOHOL
NDA NDA214988
Sources
Details